dm+d

Unassigned

New Medicines

Metastatic PIK3CA-mutant HR-positive breast cancer - with palbociclib and fulvestrant

Information

New molecular entity
Roche
Roche

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Selective PI3K alpha inhibitor
There are around 55,200 new breast cancer cases in the UK every year. About 80% of all breast cancers are ER-positive [2]. PIK3CA mutations are found in about 30-40% of breast cancers [3].
Metastatic PIK3CA-mutant HR-positive breast cancer - with palbociclib and fulvestrant
Oral